Drug intelligence / Profile preview

PF-00572778

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PF-00572778 is a small molecule drug developed by Pfizer. It acts as an antagonist of the corticotropin-releasing factor (CRF) receptor, also known as the corticotropin-releasing hormone (CRH) receptor. By blocking CRF receptors, it was designed to attenuate adrenocorticotropin (ACTH) and cortisol responses to stressors such as naloxone challenge in healthy subjects. The compound was evaluated in early clinical trials for its pharmacodynamic effects but development has been discontinued[2][1][3].

Targets

CRHR1 (Corticotropin-releasing factor receptor 1)

Beyond the preview

Go deeper on PF-00572778.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-00572778.

Explore the full profile